Chronic Low Back Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Chronic Low Back Pain Market Outlook
Thelansis’s “Chronic Low Back Pain
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Chronic Low Back Pain treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Chronic
Low Back Pain Overview
Chronic
low back pain (cLBP) is a widespread health issue with significant societal
ramifications. Chronic back pain is defined as pain that lasts for at least 12
weeks after an initial injury or underlying cause of acute low back pain has
been treated. At one year, approximately 20% of people who experience acute low
back pain develop chronic low back pain with persistent symptoms. Even if pain
persists, this does not always imply that there is a serious underlying cause
that can be easily identified and treated. The treatment successfully relieves
chronic low back pain in some cases, but pain persists in others despite
medical and surgical treatment. Patients into one of several categories: (1)
nonspecific low back pain; (2) back pain associated with a radiculopathy or
spinal stenosis; (3) back pain referred from a nonspinal source; or (4) back
pain associated with another specific spinal cause. For patients with back pain
associated with radiculopathy, magnetic resonance imaging or computed
tomography, spinal stenosis, or another specific spinal cause may establish the
diagnosis and guide management.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment